Epizyme Inc

F:EPE

Grant C. Bogle is a seasoned executive with extensive experience in the biopharmaceutical industry. Before joining Epizyme, Inc., he accumulated significant expertise in commercial strategy, sales, and marketing. At Epizyme, a biopharmaceutical company focused on developing novel epigenetic therapies for cancer patients, Grant C. Bogle served as an executive bringing his profound knowledge in the advancement of the company's strategic initiatives. His role likely involved guidance on expanding Epizyme's market presence and driving the commercial success of its innovative therapeutic products. Prior to his tenure at Epizyme, Bogle held senior positions in various biotech and pharmaceutical companies, further cementing his reputation as a leader capable of navigating the complex landscape of healthcare and biopharmaceutical development.

Dr. Jeffrey L. Kutok, M.D., Ph.D., was a prominent figure in the biotechnology and medical research sectors. He served as the Chief Scientific Officer at Epizyme Inc., a biopharmaceutical company focusing on developing novel epigenetic therapies for cancer and other serious diseases. Dr. Kutok earned his M.D. and Ph.D. degrees, contributing to his expertise in both the scientific and clinical aspects of medicine. Before joining Epizyme, he held various prestigious positions, including roles in academia as a faculty member at Harvard Medical School and a staff pathologist at Brigham and Women's Hospital. His work at Harvard and Brigham and Women's Hospital primarily involved pathology and translational research, where he gained recognition for his research in hematopathology and cancer biology. At Epizyme, Dr. Kutok was instrumental in advancing the company's research and development efforts, overseeing the scientific direction of the company, and contributing to the development of targeted epigenetic therapies. His leadership and scientific acumen played a significant role in driving Epizyme's therapeutic innovations and its mission to provide patients with new treatment options for serious diseases.

Dr. H. Robert Horvitz is an esteemed biologist celebrated for his significant contributions to the field of genetics, particularly his groundbreaking work on apoptosis, or programmed cell death. He is a Nobel Prize laureate, having been awarded the Nobel Prize in Physiology or Medicine in 2002, alongside Sydney Brenner and John E. Sulston, for their discoveries concerning genetic regulation of organ development and programmed cell death. Dr. Horvitz completed his undergraduate education at the Massachusetts Institute of Technology (MIT) and went on to earn his Ph.D. from Harvard University. He has had a long and distinguished career in academia and research, primarily based at MIT, where he serves as a professor. In addition to his academic roles, Dr. Horvitz has been involved with various biotechnology companies. He joined the board of directors of Epizyme Inc., a biopharmaceutical company focused on developing novel epigenetic therapies for cancer and other diseases. His role at Epizyme capitalizes on his extensive expertise in genetics and molecular biology. His research has broadly impacted the understanding of cellular processes and has implications for treating various diseases, including cancer. Dr. Horvitz is also a member of numerous prestigious organizations and has received several awards and honors apart from the Nobel Prize, reflecting his influence and leadership in the scientific community.

Dr. Yi Zhang is a notable scientist formerly associated with Epizyme Inc., a company focused on developing epigenetic therapies to treat cancer and other serious diseases. Dr. Zhang is well-regarded in the field of epigenetics, an area of study that examines modifications on DNA and histone proteins that affect gene expression without altering the DNA sequence itself. Before his time at Epizyme, Dr. Zhang gained recognition for his groundbreaking research in the field of chromatin biology and gene regulation. He has extensively studied the roles of histone modifications and DNA methylation in regulating gene expression, contributing significantly to the understanding of how epigenetic changes can lead to diseases like cancer. Throughout his career, Dr. Zhang has held prestigious academic positions and has been involved in numerous research projects that have had a substantial impact on molecular biology and genetics. His work has been published in leading scientific journals, making him a highly respected figure in his field. In addition to his research, Dr. Zhang has been involved in the scientific community, contributing to the advancement of epigenetic therapies through his involvement with Epizyme Inc. and other collaborative ventures aimed at translating scientific discoveries into therapeutic interventions. His work continues to influence the development of new treatment approaches that target the epigenetic components of diseases.

Jerald Korn J.D. served as the General Counsel and Chief Compliance Officer for Epizyme Inc., a biopharmaceutical company focused on developing novel epigenetic therapies for cancer and other serious diseases. In his role, Mr. Korn was responsible for overseeing the company's legal and compliance functions, guiding the organization through complex legal landscapes, managing corporate governance, and ensuring regulatory compliance. Before joining Epizyme, he brought a wealth of experience from his previous roles in legal affairs within the biotechnology sector, contributing to Epizyme's strategic development and commercial endeavors. His background in law and his experience in the life sciences industry were instrumental in supporting Epizyme's mission to bring transformative therapies to patients in need.

Joseph Beaulieu was a prominent figure at Epizyme Inc., where he contributed significantly to the company's financial and strategic operations as the Vice President of Investor Relations. His role involved fostering strong relationships with investors and analysts, and effectively communicating the company's vision, performance, and growth strategies. Before his tenure at Epizyme, he amassed extensive experience in finance and investor relations, having served in various roles that showcased his expertise in strategic communications and corporate finance. His work helped enhance the transparency and accessibility of Epizyme's financial reporting, thereby boosting investor confidence and driving the company's market presence.

Craig West, CFA, serves as the Chief Financial Officer (CFO) at Epizyme Inc. He joined the company in March 2020, bringing with him a wealth of experience in finance and investment banking, particularly in the healthcare sector. Before his tenure at Epizyme, he held the position of Senior Vice President of Corporate Strategy at Alexion Pharmaceuticals, where he oversaw financial strategy, capital allocation, and corporate development efforts. Earlier in his career, Craig West spent over a decade at Citigroup in the Global Healthcare Investment Banking division, where he advised healthcare companies on mergers and acquisitions as well as equity and debt financings. His extensive background in finance and strategic planning has been instrumental in guiding Epizyme's financial operations and growth strategies. As a Chartered Financial Analyst (CFA), Craig West brings a high level of financial expertise and analytical skills to his role at Epizyme Inc.

Dr. Mark A. De Rosch, Ph.D., served as the Chief Regulatory Officer at Epizyme Inc., a biopharmaceutical company focused on developing epigenetic therapies for cancer and other serious diseases. In his role, Dr. De Rosch was responsible for overseeing and guiding the company's regulatory strategies to ensure their therapies meet the necessary local and international regulatory requirements for development and commercialization. Before his time at Epizyme, Dr. De Rosch amassed extensive experience in regulatory affairs within the pharmaceutical and biotechnology industries. His career spans various leadership roles, where he has been integral in navigating complex regulatory environments and establishing compliance frameworks to expedite product development and approval processes. He holds a Ph.D., which underscores his strong scientific and technical background, contributing to his effectiveness in bridging regulatory sciences with drug development. Dr. De Rosch's expertise includes working with regulatory agencies like the FDA and EMA, preparing regulatory submissions, and managing interactions with these bodies to facilitate the progression of drug candidates through the clinical pipeline. His time at Epizyme was marked by a commitment to advancing the company's innovative therapies, aiming to bring meaningful change to patients with unmet medical needs.